Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients
暂无分享,去创建一个
M. Dietel | M. Untch | V. Nekljudova | S. Darb-Esfahani | B. Müller | B. Ataseven | R. Kronenwett | G. Minckwitz | A. Staebler | C. Petry | C. Solbach | B. Sinn | J. Hilfrich | G. Altmann | C. Roth | T. Kirchner
[1] F. Bertucci,et al. A refined molecular taxonomy of breast cancer , 2011, Oncogene.
[2] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.
[3] Pierre-Marie Martin,et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.
[4] L. Pusztai,et al. Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.
[5] F. Bertucci,et al. Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial , 2011, Breast Cancer Research.
[6] L. Esserman,et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.
[7] C. Sotiriou,et al. Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis. , 2011, Critical reviews in oncology/hematology.
[8] F. Bertucci,et al. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients , 2011, Breast Cancer Research and Treatment.
[9] Andrew R. Green,et al. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups , 2011, Breast Cancer Research and Treatment.
[10] F. Bertucci,et al. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer , 2011, Breast Cancer Research and Treatment.
[11] Shu Ichihara,et al. Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.
[12] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[13] P. Diest,et al. Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer , 2010, Breast Cancer Research and Treatment.
[14] Benjamin Haibe-Kains,et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues , 2009, BMC Genomics.
[15] F. Penault-Llorca,et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Axel Hausen,et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers , 2009, Breast Cancer Research and Treatment.
[18] C Caldas,et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.
[19] Ian O Ellis,et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H. Kölbl,et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.
[21] C. Sotiriou,et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.
[22] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Bergh,et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.
[24] C. Sotiriou,et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.
[25] J. Bergh,et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[27] T. Delozier,et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Joshy George,et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.
[29] Christine Desmedt,et al. Proliferation: the Most Prominent Predictor of Clinical Outcome in Breast Cancer , 2006, Cell cycle.
[30] P Kronqvist,et al. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index , 2006, Histopathology.
[31] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[32] F. Bertucci,et al. Gene expression profiling and clinical outcome in breast cancer. , 2006, Omics : a journal of integrative biology.
[33] Nobuya Sano,et al. Problems in histological grading of malignancy and its clinical significance in patients with operable Breast Cancer , 2006, Breast cancer.
[34] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. V. van Diest,et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Vincent-Salomon,et al. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. , 2004, Anticancer research.
[37] J. Baak,et al. Prognostic value of proliferation in invasive breast cancer: a review , 2004, Journal of Clinical Pathology.
[38] A. Hanby,et al. Mitotic counts provide additional prognostic information in grade II mammary carcinoma , 2002, The Journal of pathology.
[39] M. Daidone,et al. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.
[40] M. J. van de Vijver,et al. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial , 2000, Cancer.
[41] S. Edge,et al. Prognostic factors in breast cancer , 2005 .
[42] M. Fernö,et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. , 1999, Journal of the National Cancer Institute.
[43] A. Thor,et al. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] K Vajda,et al. [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.
[45] P. V. van Diest,et al. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. , 1995, Human pathology.
[46] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[47] C. Quinn,et al. The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables , 1990, The Journal of pathology.
[48] S Friedman,et al. Prognostic value of histologic grade nuclear components of Scarff‐Bloom‐Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas , 1989, Cancer.
[49] H. Bloom,et al. Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.